pentazirinocyclodiphosphathiazene (SOAZ)

Subscribe to Selected New Research on pentazirinocyclodiphosphathiazene

6 relevant articles (1 outcomes, 0 trials/studies) found for this Bio-Agent

Description: structure given in first source

Also Known As:

SOAZ; 1,3,3,5,5-pentazridino-1-thia-2,4,6-triaza-3,5-diphosphorine-1-oxide; pentakis(aziridino)thiatriazadiphosphorine oxide; pentazirino-cyclo-diphosphathiazene; 1H-1,2,4,6,3,5-Thiatriazadiphosphorine, 1,3,3,5,5-pentakis(1-aziridinyl)-3,3,5,5-tetrahydro-, 1-oxide

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azirines

pentazirinocyclodiphosphathiazene: 6

Related Diseases

1.	Leukemia L1210 12/01/1986 - "SOAz showed marked antitumor effect against early-stage L1210 leukemia, and was also effective against advanced-stage L1210 leukemia" 10/01/1982 - "In contrast to cyclophosphamide, SOAz was active against B16 melanoma and Meth A, and demonstrated high activity against a subline of L1210 leukemia resistant to cyclophosphamide." 10/01/1982 - "The optimal treatment regimens of SOAz (i.p.) gave 262% and 134% increase in life span (ILS) in mice with P388 leukemia and L1210 leukemia implanted intraperitoneally, respectively, and 239% ILS in rats with Yoshida sarcoma of which 86% survived for 60 d after intraperitoneal tumor implantation" Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 05/01/1984 - "Eleven patients with advanced cancer were treated with SOAz, the first aziridino substituted inorganic heterocyclic compound to undergo phase I clinical trials" 10/01/1982 - "1,3,3,5,5-Pentaziridino-1-thia-2,4,6-triaza-3,5-diphosphorine-1-oxide (SOAz), a new antitumor agent, was evaluated for antitumor activity against various mouse- and rat-tumor systems" 10/01/1982 - "The optimal treatment regimens of SOAz (i.p.) gave 262% and 134% increase in life span (ILS) in mice with P388 leukemia and L1210 leukemia implanted intraperitoneally, respectively, and 239% ILS in rats with Yoshida sarcoma of which 86% survived for 60 d after intraperitoneal tumor implantation" Get all the results and reference details, order at left...
3.	Leukemia P388 10/01/1982 - "The optimal treatment regimens of SOAz (i.p.) gave 262% and 134% increase in life span (ILS) in mice with P388 leukemia and L1210 leukemia implanted intraperitoneally, respectively, and 239% ILS in rats with Yoshida sarcoma of which 86% survived for 60 d after intraperitoneal tumor implantation" 12/01/1986 - "SOAz was found to have similar activity to carbazilquinone, cyclophosphamide or mitomycin C on P388 leukemia" Get all the results and reference details, order at left...
4.	Small Cell Carcinoma (Small Cell Lung Cancer) 06/01/1986 - "We investigated the mode of action on DNA of three different compounds, 1,3,3,5,5-pentakis (1-aziridinyl)-1 lambda 6,2,4,6,3 lambda 5,5 lambda 5-thiatriazadiphosphorine -1-oxide (SOAz), trans-1,3-bis(1-aziridinyl)-1,3,5,5-tetrakis (methylamino)-2,4,6,1 lambda 5,3 lambda 5,5 lambda 5-triazatriphosphorine (AZP), and 1,trans-5-bis(1-azaridinyl)-gem-1,3,3'-cis-5,7,7'-hexakis (methylamino)-2,4,6,8,1 lambda 5,3 lambda 5,5 lambda 5,7 lambda 5 -tetraazatetraphosophocine (AZM), of this group in the Ehrlich ascites tumor cell line (EAT) and a human small cell carcinoma cell line" Get all the results and reference details, order at left...
5.	Yoshida Sarcoma 10/01/1982 - "The optimal treatment regimens of SOAz (i.p.) gave 262% and 134% increase in life span (ILS) in mice with P388 leukemia and L1210 leukemia implanted intraperitoneally, respectively, and 239% ILS in rats with Yoshida sarcoma of which 86% survived for 60 d after intraperitoneal tumor implantation" Get all the results and reference details, order at left...
10 Diseases and 6 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Cyclophosphamide (Cytoxan)
2.	Mitomycin (Mitomycin-C)
3.	DNA (Deoxyribonucleic Acid)
4.	Carbazilquinone (Carboquone)
5.	Antigen-Antibody Complex (Immune Complex)
5 Drugs and Important Bio-Agents and 4 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>